Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

被引：1

作者：

Jose Casanova, Maria ^{[1
,2
]}

Caballol, Berta ^{[3
,4
]}

Jose Garcia, Maria ^{[5
,6
]}

Mesonero, Francisco ^{[7
]}

Rubin de Celix, Cristina ^{[1
,2
]}

Suarez-Alvarez, Patricia ^{[8
]}

Ferreiro-Iglesias, Rocio ^{[9
,10
]}

Martin-Rodriguez, Maria del Mar ^{[11
]}

de Francisco, Ruth ^{[12
,13
]}

Varela-Trastoy, Pilar ^{[14
]}

Bastida, Guillermo ^{[15
,16
]}

Carrillo-Palau, Marta ^{[17
]}

Nunez-Ortiz, Andrea ^{[18
]}

Ramirez-de la Piscina, Patricia ^{[19
]}

Ceballos, Daniel ^{[20
]}

Hervias-Cruz, Daniel ^{[21
]}

Munoz-Perez, Roser ^{[22
,23
]}

Velayos, Benito ^{[24
]}

Bermejo, Fernando ^{[25
,26
]}

Busquets, David ^{[27
]}

Cabacino, Manuel ^{[28
]}

Camo-Monterde, Patricia ^{[29
]}

Marin-Jimenez, Ignacio ^{[30
,31
]}

Munoz, Carmen ^{[32
]}

de la Pena-Negro, Luisa Carmen ^{[33
]}

Sierra-Moros, Eva ^{[34
]}

Barrio, Jesus ^{[35
]}

Brunet-Mas, Eduard ^{[36
,37
]}

Bujanda, Luis ^{[38
,39
]}

Canete, Fiorella ^{[40
,41
]}

Gomollon, Fernando ^{[42
,43
]}

Mancenido-Marcos, Noemi ^{[44
]}

Rodriguez-Lago, Iago ^{[45
]}

Rodriguez-Grau, Maria Carmen ^{[46
]}

Sicilia, Beatriz ^{[47
]}

Torra-Alsina, Sandra ^{[48
]}

Arranz-Hernandez, Laura ^{[49
]}

Carpio, Daniel ^{[50
]}

Garcia-Sepulcre, Mariana Fe A. ^{[51
]}

Gonzalez-Munoza, Carlos ^{[52
]}

Maria Huguet, Jose ^{[53
]}

Marquez-Mosquera, Lucia ^{[54
,55
]}

Lopez-Serrano, Maria Pilar ^{[56
]}

Ponferrada-Diaz, Angel ^{[57
]}

Chaparro, Maria ^{[1
,2
]}

Gisbert, Javier P. ^{[1
,2
]}

机构：

[1] Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS Princesa, Hosp Univ La Princesa, Dept Gastroenterol, Madrid, Spain

[2] CIBEREHD, Madrid, Spain

[3] IDIBAPS, Hosp Clin & Prov, Dept Gastroenterol, Barcelona, Spain

[4] CIBEREHD, Barcelona, Spain

[5] Hosp Univ Marques Valdecilla, Dept Gastroenterol, Santander, Spain

[6] IDIVAL, Santander, Spain

[7] Hosp Univ Ramon y Cajal, Dept Gastroenterol, Madrid, Spain

[8] Complejo Asistencial Univ Leon, Dept Gastroenterol, Leon, Spain

[9] Hosp Clin Univ Santiago de Compostela, Dept Gastroenterol, Santiago De Compostela, Spain

[10] Inst Invest Sanitaria Santiago de Compostela IDIS, Santiago De Compostela, Spain

[11] Hosp Univ Virgen de las Nieves, Dept Gastroenterol, Granada, Spain

[12] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo, Spain

[13] ISPA, Oviedo, Spain

[14] Hosp Univ Cabuenes, Dept Gastroenterol, Gijon, Spain

[15] Hosp Univ & Politecn La Fe, Dept Gastroenterol, Valencia, Spain

[16] CIBEREHD, Valencia, Spain

[17] Hosp Univ Canarias, Dept Gastroenterol, San Cristobal la Laguna, Spain

[18] Hosp Univ Virgen del Rocio, Dept Gastroenterol, Seville, Spain

[19] Hosp HUA Alava, Dept Gastroenterol, Vitoria, Spain

[20] Hosp Univ Gran Canaria Dr Negrin, Dept Gastroenterol, Las Palmas Gran Canaria, Spain

[21] Hosp Gen Univ Ciudad Real, Dept Gastroenterol, Ciudad Real, Spain

[22] Hosp Gen Univ Dr Balmis, Dept Gastroenterol, Alicante, Spain

[23] CIBEREHD, Alicante, Spain

[24] Hosp Clin Valladolid, Dept Gastroenterol, Valladolid, Spain

[25] Hosp Univ Fuenlabrada, Dept Gastroenterol, Madrid, Spain

[26] Inst Invest Hosp Univ La Paz IdiPAZ, Madrid, Spain

[27] Hosp Univ Girona Dr Josep Trueta, Dept Gastroenterol, Girona, Spain

[28] Hosp Gen Univ Castellon, Dept Gastroenterol, Castellon de La Plana, Spain

[29] Hosp Gen San Jorge, Dept Gastroenterol, Huesca, Spain

[30] Hosp Univ Gregorio Maranon, Dept Gastroenterol, IiSGM, Madrid, Spain

[31] Univ Complutense Madrid, Madrid, Spain

[32] Hosp Univ Basurto, Dept Gastroenterol, Bilbao, Spain

[33] Hosp Univ Bellvitge, Dept Gastroenterol, Barcelona, Spain

[34] Hosp Univ Miguel Servet, Dept Gastroenterol, Zaragoza, Spain

[35] Hosp Univ Rio Hortega, Dept Gastroenterol, Valladolid, Spain

[36] Hosp Univ Parc Tauli, Dept Gastroenterol, Sabadell, Spain

[37] CIBEREHD, Barcelona, Spain

[38] Univ Pais Vasco UPV EHU, Biodonostia Hlth Res Inst, Hosp Univ Donostia, Dept Gastroenterol, Donostia San Sebastian, Spain

[39] CIBEREHD, Donostia San Sebastian, Spain

[40] Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Badalona, Spain

[41] CIBEREHD, Badalona, Spain

[42] Inst Invest Sanitaria Aragon IIS Aragon, Hosp Clin Univ Lozano Blesa, Dept Gastroenterol, Zaragoza, Spain

[43] CIBEREHD, Zaragoza, Spain

[44] Hosp Univ Infanta Sofia, Dept Gastroenterol, Madrid, Spain

[45] Inst Invest Sanitaria BioBizkaia, Hosp Univ Galdakao, Dept Gastroenterol, Vizcaya, Spain

[46] Hosp Univ Henares, Dept Gastroenterol, Madrid, Spain

[47] Hosp Univ Burgos, Dept Gastroenterol, Burgos, Spain

[48] Parc Sanitari Sant Joan Deu, Dept Gastroenterol, Sant Boi De Llobregat, Spain

[49] Hosp Univ Nuestra Senora Candelaria, Dept Gastroenterol, Santa Cruz De Tenerife, CA, Spain

[50] Complexo Hosp Univ Pontevedra, Dept Gastroenterol, Pontevedra, Spain

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷 / 11期

关键词：

Ustekinumab; Vedolizumab; Complex perianal fistula; SUBCUTANEOUS USTEKINUMAB; MULTICENTER; EXPERIENCE; MANAGEMENT; INFLIXIMAB; EFFICACY;

D O I：

10.1016/j.dld.2024.05.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context. Methods: Crohn's disease patients who had received ustekinumab or vedolizumab for the indication of active complex perianal fistula, were included. Clinical remission was defined according to Fistula Drainage Assessment Index (no drainage through the fistula upon gentle pressure) based on physicians' assessment. Results: Of 155 patients, 136 received ustekinumab, and 35 vedolizumab (16 received both). Median follow-up for ustekinumab was 27 months. Among those on ustekinumab, 54 % achieved remission, and within this group, 27 % relapsed during follow-up. The incidence rate of relapse was 11 % per patient-year. Multivariate analysis found no variables associated with treatment discontinuation or relapse. Median follow-up time for patients receiving vedolizumab was 19 months. Remission was achieved in 46 % of the patients receiving vedolizumab, and among them, 20 % relapsed during follow-up. The incidence rate of relapse was 7 % per patient-year. Adverse events were mild in 6 % on ustekinumab and 8 % on vedolizumab. Conclusion: Ustekinumab and vedolizumab appear effective, achieving remission in around half of complex perianal fistula patients, with favorable safety profiles. (c) 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：1845 / 1853

页数：9

共 50 条

[21] Effectiveness and safety of ustekinumab in elderly Crohn's Disease patients
Nunez, I. Ruiz
Sauca, L. Morera
Dominguez, R. E. Madrigal
Andres, J. Barrio
Santos, A. De Prado
Roman, L. Mata
Munoz, M. A. Marinero
Alonso, J. Garcia
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1436 - i1436
[22] Safety and effectiveness of ustekinumab in elderly Crohn's disease patients
Fiske, Joseph
Liu, Eleanor
Limdi, Jimmy K.
Conley, Thomas E.
Townsend, Tristan
Davies, Mike
Brockwell, Robert
Baig, Daniyal
Abdelbadiee, Sherif
Uney, Anastasia
Liaros, Angela
Gaba, Waqas
Smith, Philip J.
Flanagan, Paul K.
Subramanian, Sreedhar
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (11) : 1132 - 1139
[23] Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice
Saldana Duenas, Cristina
Rullan Iriarte, Maria
Elosua Gonzalez, Alfonso
Rodriguez Gutierrez, Cristina
Rubio Iturria, Saioa
Nantes Castillejo, Oscar
GASTROENTEROLOGIA Y HEPATOLOGIA, 2020, 43 (09): : 497 - 505
[24] A PILOT STUDY ON THE USE OF USTEKINUMAB IN REFRACTORY PERIANAL CROHN'S DISEASE
Crispino, F.
Brinch, D.
Busacca, A.
Carrozza, L.
Cocorullo, G.
Cappello, M.
DIGESTIVE AND LIVER DISEASE, 2021, 53 : S164 - S164
[25] Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease
Dart, Robin J.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (09) : 1028 - 1029
[26] Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn's disease: a comparative study
Dar, Lior
Shani, Uria
Dotan, Arad
Ukashi, Offir
Ben-Horin, Shomron
Kopylov, Uri
Levartovsky, Asaf
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
[27] VEDOLIZUMAB COMPARED WITH INFLIXIMAB FOR PERIANAL FISTULA CLOSURE IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
Gold, Stephanie
Cohen-Mekelburg, Shirley A.
Schneider, Yecheskel
Bosworth, Brian P.
Scherl, Ellen
Steinlauf, Adam F.
GASTROENTEROLOGY, 2018, 154 (06) : S370 - S370
[28] Complex perianal fistula in a patient with Crohn's disease treated with fistula laser closure therapy - A video vignette
Vela, Alberto Gallego
Bujedo, Lourdes Gomez
Membrives, Pablo Parra
COLORECTAL DISEASE, 2023, 25 (11) : 2273 - 2275
[29] Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study
Schwartz, David A.
Peyrin-Biroulet, Laurent
Lasch, Karen
Adsul, Shashi
Danese, Silvio
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (05) : 1059 - +
[30] ASSOCIATION OF USTEKINUMAB SERUM CONCENTRATIONS AND PERIANAL FISTULA RESOLUTION IN THE CROHN'S DISEASE UNITI PROGRAM
Sands, Bruce E.
Kramer, Brian C.
Gasink, Christopher
Jacobstein, Douglas
Gao, Long-Long
Ma, Tony
Adedokun, Omoniyi J.
Colombel, Jean Frederic
Schwartz, David A.
GASTROENTEROLOGY, 2019, 156 (06) : S1099 - S1100

← 1 2 3 4 5 →